Efficient Persistence of Extrachromosomal KSHV DNA Mediated by Latency-Associated Nuclear Antigen
10.1126/science.284.5414.641
Crossref journal-article
American Association for the Advancement of Science (AAAS)
Science (221)
Abstract

Primary effusion lymphoma (PEL) cells harbor Kaposi's sarcoma–associated herpesvirus (KSHV) episomes and express a KSHV-encoded latency-associated nuclear antigen (LANA). In PEL cells, LANA and KSHV DNA colocalized in dots in interphase nuclei and along mitotic chromosomes. In the absence of KSHV DNA, LANA was diffusely distributed in the nucleus or on mitotic chromosomes. In lymphoblasts, LANA was necessary and sufficient for the persistence of episomes containing a specific KSHV DNA fragment. Furthermore, LANA colocalized with the artificial KSHV DNA episomes in nuclei and along mitotic chromosomes. These results support a model in which LANA tethers KSHV DNA to chromosomes during mitosis to enable the efficient segregation of KSHV episomes to progeny cells.

Bibliography

Ballestas, M. E., Chatis, P. A., & Kaye, K. M. (1999). Efficient Persistence of Extrachromosomal KSHV DNA Mediated by Latency-Associated Nuclear Antigen. Science, 284(5414), 641–644.

Authors 3
  1. Mary E. Ballestas (first)
  2. Pamela A. Chatis (additional)
  3. Kenneth M. Kaye (additional)
References 45 Referenced 603
  1. 10.1126/science.7997879
  2. Moore P. S., et al., J. Virol. 70, 549 (1996); (10.1128/jvi.70.1.549-558.1996) / J. Virol. by Moore P. S. (1996)
  3. Gao S.-J., et al., N. Engl. J. Med. 335, 233 (1996); (10.1056/NEJM199607253350403) / N. Engl. J. Med. by Gao S.-J. (1996)
  4. Moore P. S., Chang Y., ibid. 332, 1181 (1995). / ibid. by Moore P. S. (1995)
  5. Cesarman E., et al., Blood 86, 2708 (1995). (10.1182/blood.V86.7.2708.2708) / Blood by Cesarman E. (1995)
  6. 10.1126/science.276.5320.1851
  7. Soulier J., et al., Blood 86, 1276 (1995); (10.1182/blood.V86.4.1276.bloodjournal8641276) / Blood by Soulier J. (1995)
  8. Cesarman E., Chang Y., Moore P. S., Said J. W., Knowles D. M., N. Engl. J. Med. 332, 1186 (1995). (10.1056/NEJM199505043321802) / N. Engl. J. Med. by Cesarman E. (1995)
  9. Decker L. L., et al., J. Exp. Med. 184, 283 (1996). (10.1084/jem.184.1.283) / J. Exp. Med. by Decker L. L. (1996)
  10. Yates J., Warren N., Reisman D., Sugden B., Proc. Natl. Acad. Sci. U.S.A. 81, 3806 (1984); (10.1073/pnas.81.12.3806) / Proc. Natl. Acad. Sci. U.S.A. by Yates J. (1984)
  11. Yates J. L., Warren N., Sugden B., Nature 313, 812 (1985). (10.1038/313812a0) / Nature by Yates J. L. (1985)
  12. Rawlins D. R., Milman G., Hayward S. D., Hayward G. S., Cell 42, 859 (1985). (10.1016/0092-8674(85)90282-X) / Cell by Rawlins D. R. (1985)
  13. Kung S.-H., Medveczky P. G., J. Virol. 70, 1738 (1996). (10.1128/jvi.70.3.1738-1744.1996) / J. Virol. by Kung S.-H. (1996)
  14. 10.1073/pnas.93.25.14862
  15. Kellam P., et al., J. Hum. Virol. 1, 19 (1997); / J. Hum. Virol. by Kellam P. (1997)
  16. Rainbow L., et al., J. Virol. 71, 5915 (1997); (10.1128/jvi.71.8.5915-5921.1997) / J. Virol. by Rainbow L. (1997)
  17. Kedes D. H., Lagunoff M., Renne R., Ganem D., J. Clin. Invest. 100, 2606 (1997); (10.1172/JCI119804) / J. Clin. Invest. by Kedes D. H. (1997)
  18. Neipel F., Albrecht J. C., Fleckenstein B., J. Virol. 71, 4187 (1997). (10.1128/jvi.71.6.4187-4192.1997) / J. Virol. by Neipel F. (1997)
  19. Albrecht J. C., et al., J. Virol. 66, 5047 (1992); (10.1128/jvi.66.8.5047-5058.1992) / J. Virol. by Albrecht J. C. (1992)
  20. Virgin H. W., et al., ibid. 71, 5894 (1997). / ibid. by Virgin H. W. (1997)
  21. Gao S. J., et al., Nature Med. 2, 925 (1996); (10.1038/nm0896-925) / Nature Med. by Gao S. J. (1996)
  22. ; D. H. Kedes et al. ibid. p. 918; D. Jones et al. N. Engl. J. Med. 339 444 (1998);
  23. 10.1038/nm0396-342
  24. Szekely L., et al., J. Gen. Virol. 79, 1445 (1998). (10.1099/0022-1317-79-6-1445) / J. Gen. Virol. by Szekely L. (1998)
  25. FISH was performed with TSA-Direct (NEN Life Science Products). Colcemid treatment and hypotonic swelling of cells was performed as described in (19). Cells were fixed in 4% paraformaldehyde at room temperature for 10 min and then fixed in 70% ethanol at 4°C for 10 min. Fixed cells were permeabilized with 0.5% Triton-X 100 and overlaid with DNA in situ hybridization solution (DAKO Carpinteria CA) containing 20 ng of a probe that was labeled with biotin and nick translated from pBSLANA. pBSLANA was constructed by subcloning the 4.7-kb KSHV genomic Sac I fragment flanking ORF 73 from the L54 library phage (8) into pBluescript (Stratagene). After denaturation of DNA at 93°C for 5 min slides were incubated for 4 hours at 37°C washed in 0.2× standard saline citrate for 30 min at 45°C and blocked in TNB (0.1 M tris-HCl pH 7.5 0.15 M NaCl 0.5% blocking reagent) at room temperature for 30 min. Slides were then incubated with streptavidin–horseradish peroxidase (1:100) for 30 min at 37°C and incubated with cyanine 3-tyramide (1:50) for 10 min at room temperature. After FISH cells were incubated with BJAB cell extract–adsorbed KSHV immune serum (1:50) followed by secondary fluorescein isothiocyanate–conjugated antibody and counterstained with DAPI (1 μg/ml) in methanol for 15 min. For two-color fluorescence DAPI was omitted.
  26. Genomic ORF 73 was cloned downstream of the simian virus 40 (SV40) promoter in pSG5 (Stratagene) (termed pSG5LANA) or in pSG5FLAG [
  27. Hatzivassiliou E., Cardot P., Zannis V. I., Mitsialis S. A., Biochemistry 36, 9221 (1997); (10.1021/bi963145k) / Biochemistry by Hatzivassiliou E. (1997)
  28. ] (termed pSG5 F-LANA). In pSG5 F-LANA the four NH 2 -terminal LANA amino acids are replaced with the FLAG epitope (DYKDDDDKV) (22). LANA stable cell lines were generated by electroporating pSG5LANA or pSG5 F-LANA and a plasmid encoding the hygromycin-resistance gene downstream of an SV40 promoter into BJAB cells [
  29. Kaye K. M., Izumi K. M., Mosialos G., Kieff E., J. Virol. 69, 675 (1995); (10.1128/jvi.69.2.675-683.1995) / J. Virol. by Kaye K. M. (1995)
  30. Liebowitz D., Mannick J., Takada K., Kieff E., ibid. 66, 4612 (1992); / ibid. by Liebowitz D. (1992)
  31. ]. After 48 hours cells were seeded into microtiter plates and hygromycin-resistant clones were selected. Hygromycin-resistant BJAB cells expressing pSG5LANA or pSG5 F-LANA were transfected with 25 μg of the Z6 or Z8 cosmid. Z6 contains KSHV sequence including the terminal repeats and the first ∼33 kb of the BC-1 genome cloned into S-Cos1 (Stratagene) and Z8 contains nucleotides ∼73 000 to 107 000 of BC-1 KSHV cloned into S-Cos1 (8). S-Cos1 encodes the neomycin-resistance gene downstream of an SV40 promoter and provides G418 resistance. After 48 hours cells were placed under G418 selection. For subclone analysis the Z6 cosmid was digested with Hind III and religated resulting in the deletion of KSHV sequences after the first ∼13 kb of the genome (Z6-13). The two largest remaining Z6 KSHV Hind III fragments of ∼7 and ∼11 kb were cloned into pREP9 (Invitrogen) after the deletion of the pREP9 sequences between Cla I and Kpn I (Z6-7 and Z6-11 respectively). pREP9 encodes the neomycin-resistance gene downstream of a thymidine kinase promoter and provides G418 resistance. The Z6 subclones were transfected into BJAB/F-LANA or BJAB cells and selected for G418 resistance as above.
  32. M. E. Ballestas and K. M. Kaye unpublished data.
  33. Gardella gels were prepared as previously described [
  34. Gardella T., Medveczky P., Sairenji T., Mulder C., J. Virol. 50, 248 (1984)]. (10.1128/jvi.50.1.248-254.1984) / J. Virol. by Gardella T. (1984)
  35. Bochkarev A., et al., Cell 84, 791 (1996). (10.1016/S0092-8674(00)81056-9) / Cell by Bochkarev A. (1996)
  36. Reisman D., Sugden B., Mol. Cell. Biol. 6, 3838 (1986). / Mol. Cell. Biol. by Reisman D. (1986)
  37. Petti L., Sample C., Kieff E., Virology 176, 563 (1990). (10.1016/0042-6822(90)90027-O) / Virology by Petti L. (1990)
  38. Grogan E., et al., Proc. Natl. Acad. Sci. U.S.A. 80, 7650 (1983); (10.1073/pnas.80.24.7650) / Proc. Natl. Acad. Sci. U.S.A. by Grogan E. (1983)
  39. Reedman B. M., Klein G., Int. J. Cancer 11, 499 (1973). (10.1002/ijc.2910110302) / Int. J. Cancer by Reedman B. M. (1973)
  40. 10.1073/pnas.95.8.4338
  41. 10.1128/JVI.72.3.2079-2088.1998
  42. Harris A., Young B. D., Griffin B. E., ibid. 56, 328 (1985). / ibid. by Harris A. (1985)
  43. Single-letter abbreviations for the amino acid residues are as follows: D Asp; K Lys; V Val; and Y Tyr.
  44. Renne R., Lagunoff M., Zhong W., Ganem D., J. Virol. 70, 8151 (1996). (10.1128/jvi.70.11.8151-8154.1996) / J. Virol. by Renne R. (1996)
  45. We thank E. Kieff for helpful discussions and P. Marks for assistance with microscopy for Fig. 2. This work was supported by grant CA67380-04 (K.M.K.) from the National Cancer Institute.
Dates
Type When
Created 23 years, 1 month ago (July 27, 2002, 5:40 a.m.)
Deposited 1 year, 7 months ago (Jan. 13, 2024, 4:21 a.m.)
Indexed 1 day, 12 hours ago (Sept. 4, 2025, 9:56 a.m.)
Issued 26 years, 4 months ago (April 23, 1999)
Published 26 years, 4 months ago (April 23, 1999)
Published Print 26 years, 4 months ago (April 23, 1999)
Funders 0

None

@article{Ballestas_1999, title={Efficient Persistence of Extrachromosomal KSHV DNA Mediated by Latency-Associated Nuclear Antigen}, volume={284}, ISSN={1095-9203}, url={http://dx.doi.org/10.1126/science.284.5414.641}, DOI={10.1126/science.284.5414.641}, number={5414}, journal={Science}, publisher={American Association for the Advancement of Science (AAAS)}, author={Ballestas, Mary E. and Chatis, Pamela A. and Kaye, Kenneth M.}, year={1999}, month=apr, pages={641–644} }